Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) Price Target at $30.50

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received an average recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $30.50.

Several equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group assumed coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company.

Insiders Place Their Bets

In other Tyra Biosciences news, Director Nina S. Kjellson sold 7,779 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the completion of the sale, the director now owns 447,857 shares of the company’s stock, valued at $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 21,998 shares of company stock valued at $344,818 over the last 90 days. 15.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tyra Biosciences

A number of large investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. lifted its holdings in shares of Tyra Biosciences by 9.0% during the third quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock worth $1,806,000 after buying an additional 6,318 shares during the last quarter. Quest Partners LLC acquired a new position in shares of Tyra Biosciences during the third quarter worth approximately $491,000. Jennison Associates LLC lifted its holdings in shares of Tyra Biosciences by 5.9% during the third quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock worth $3,719,000 after buying an additional 8,837 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Tyra Biosciences by 2.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after buying an additional 3,792 shares during the last quarter. Finally, Valence8 US LP acquired a new position in shares of Tyra Biosciences during the third quarter worth approximately $310,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Shares of TYRA opened at $11.71 on Wednesday. The company has a market capitalization of $592.56 million, a price-to-earnings ratio of -7.27 and a beta of 1.05. Tyra Biosciences has a fifty-two week low of $11.53 and a fifty-two week high of $29.60. The business’s 50-day moving average is $14.26 and its 200-day moving average is $17.96.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.